Healthcare services company Agilon Health (NYSE: AGL) announced better-than-expected revenue in Q3 2026, with sales up 5.9% year on year to $1.52 billion. The company’s full-year revenue guidance of $5.88 billion at the midpoint came in 0.9% above analysts’ estimates. Its GAAP profit of $1.97 per share was significantly above analysts’ consensus estimates.
Is now the time to buy AGL? Find out in our full research report (it’s free for active Edge members).
agilon health (AGL) Q3 2026 highlights:
- Revenue $1.52 billion vs S&P analysts’ estimates of $1.46 billion (5.9% year-on-year growth, 4.2% beat)
- EPS (GAAP) $1.97 vs analyst estimates of -$1.47 (significant beat)
- Adjusted EBITDA $63.68 million vs analyst estimates of $686,860 (4.2% margin, significant beat)
- Revenue guidance The company lifted its revenue guidance for the full year to $5.88 billion at the midpoint from $5.82 billion, a 1.1% increase
- EBITDA guidance $150 million at the midpoint for the full year, above analyst estimates of $86.41 million
- Operating margin 1.6%, up from -9.1% in the same quarter last year
- Customers 566,000, up from 549,000 in the previous quarter
- Market capitalization $1.62 billion
StockStory’s take
Agilon health’s third quarter results received a positive market response, propelled by notable gains in operational efficiency and clinical program performance. Management pointed to improved identification and treatment of complex conditions such as heart failure, as well as enhanced support for primary care partners, as key contributors. CEO Tim O’Rourke highlighted technology-enabled clinical pathways and investments in data infrastructure as central to reducing unnecessary medical costs and improving patient outcomes.
Looking forward, agilon’s updated guidance reflects confidence in the scalability of its value-based care platform and further penetration of its Accountable Care Organization (ACO) business. Management emphasized continued investments in technology and clinical programs, particularly in expanding heart failure, dementia, and lung health pathways. CFO Jeff Schwaneke noted that disciplined payer contracting and measured growth in new and existing markets will be crucial to sustaining improved margins and driving long-term profitability.
Key insights from management’s remarks
Management attributed the quarter’s performance to improved execution in clinical pathways, disciplined contracting, and data-driven support for physician partners, leading to higher revenue and margin expansion.
- Clinical pathway progress: Enhanced identification and treatment for chronic conditions, especially heart failure, drove better outcomes and reduced hospitalizations among Medicare Advantage members. O’Rourke described a case where technology-enabled screening led to earlier intervention, highlighting the impact of such programs on both patient health and medical expense control.
- Technology and data investments: Management credited improved data pipelines and AI-enabled tools for enabling earlier detection of high-risk patients and deeper integration into primary care workflows. These capabilities allowed for more consistent application of best practices and reduced performance variability across the network.
- ACO business expansion: The company expanded ACO partnerships, particularly through the Medicare Shared Savings Program (MSSP), with expectations for 40-50% ACO membership growth in 2027. O’Rourke said these expansions demonstrate the scalability of the agilon platform and the trust built with physician partners.
- Disciplined growth and contracting: Agilon maintained a measured approach to entering new markets and contracts, prioritizing profitability and alignment with its care model. Schwaneke noted that recent membership declines reflect strategic market exits to focus on higher-margin opportunities, with new partnerships supporting future embedded growth.
- Quality and outcomes focus: The company achieved high quality scores, with 4.2-star average performance and 5-star results in key measures like cardiovascular disease and cancer screenings. Management linked this to proactive care gap closure and strong engagement with physician partners, supporting both clinical outcomes and payer relationships.
Drivers of future performance
Management expects continued gains from programmatic clinical initiatives and disciplined market expansion to be the main drivers of guidance.
- Expansion of clinical programs: The rollout of heart failure, dementia, and lung health pathways is expected to deepen in coming quarters. Management believes that standardizing these programs and increasing virtual pharmacy adoption will further improve patient outcomes and control medical costs, creating a scalable model for new and existing partners.
- Growth in ACO segment: Agilon anticipates significant growth in ACO membership in 2027 from recent MSSP expansions. Management expects this segment to contribute steadily to adjusted EBITDA as new groups are integrated and performance variability is reduced through operational best practices.
- Contracting discipline and cost controls: Schwaneke emphasized the importance of ongoing payer negotiations and prudent cost trend assumptions. The company plans to continue focusing on high-value, risk-bearing contracts while mitigating exposure to less predictable elements like Part D and ensuring that margin improvements are sustainable.
Catalysts in upcoming quarters
Looking ahead, our analysts will closely monitor (1) the pace of ACO membership growth and successful onboarding of new physician partners, (2) further rollout and adoption of technology-enabled clinical pathways for chronic conditions, and (3) evidence that payer contracting continues to drive margin improvement without sacrificing growth. Progress in integrating data systems and expanding quality initiatives will also be key indicators of sustained performance.
agilon health currently trades at $108.33, up from $96.23 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Our favorite stocks right now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
